Clinical Trials Logo
  1. Home
  2. Advanced Melanoma
  3. NCT02738489

A Study to Evaluate the Safety and Tolerability of Using the SHR-1210 in Patients With Advanced Melanoma

Advanced Melanoma Clinical Trial

Official title:
An Open-Label, Single Center, Nonrandomized, Dose-Escalation Phase 1 Study to Evaluate Safety and Tolerability of SHR-1210 in Subjects With Advanced Melanoma

Clinical Trial Summary

This is an open-label, single center, non-randomized, dose escalation phase I trial to evaluate safety and tolerability of SHR-1210 (camrelizumab) in patients with advanced melanoma with disease progression after standard treatment, unresectable lesions, or metastases. Between Apr 13, 2016, and Jan 8, 2020, 36 patients were enrolled from Beijing Cancer Hospital.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT02738489
Study type Interventional
Source Jiangsu HengRui Medicine Co., Ltd.
Contact
Status Completed
Phase Phase 1
Start date April 13, 2016
Completion date January 8, 2020
View Details
See also
  Status Clinical Trial Phase
Recruiting NCT05039801 - IACS-6274 With or Without Bevacizumab and Paclitaxel for the Treatment of Advanced Solid Tumors Phase 1
Terminated NCT04894994 - FLX475 in Combination With Ipilimumab in Advanced Melanoma Phase 2
Completed NCT01621490 - PH 1 Biomarker Study of Nivolumab and Ipilimumab and Nivolumab in Combination With Ipilimumab in Advanced Melanoma Phase 1
Recruiting NCT05098184 - Study on TIL for the Treatment of Advanced Melanoma Early Phase 1
Completed NCT02177110 - A Translational Systems Medicine Approach to Provide Predictive Capacity for Therapy Response in Advanced or Metastatic Malignant Melanoma
Completed NCT00197912 - Dendritic Cell Based Therapy of Malignant Melanoma Phase 1/Phase 2
Completed NCT04165967 - Adoptive Tumor-infiltrating Lymphocyte Transfer With Nivolumab for Melanoma Phase 1
Active, not recruiting NCT04495257 - A Study of APX005M in Combination With Nivolumab and Ipilimumab in Treatment Naïve Patients With Advanced Melanoma or Renal Cell Carcinoma (RCC) Phase 1
Recruiting NCT05968690 - Naltrexone and Propranolol Combined With Immunotherapy Phase 1
Active, not recruiting NCT03200847 - Pembrolizumab and All-Trans Retinoic Acid Combination Treatment of Advanced Melanoma Phase 1/Phase 2
Recruiting NCT05105100 - Peripheral T Cell Determinants of Response and Resistance to Pembrolizumab in Melanoma
Completed NCT02171286 - The Oncopanel Pilot (TOP) Study N/A
Terminated NCT01453361 - Phase II FANG™ in Advanced Melanoma Phase 2
Recruiting NCT05120024 - Multicenter Study of Safety and Efficacy of Prolgolimab in Patients With Advanced Melanoma in Routine Clinical Practice
Active, not recruiting NCT04514484 - Testing the Combination of the Anti-cancer Drugs XL184 (Cabozantinib) and Nivolumab in Patients With Advanced Cancer and HIV Phase 1
Active, not recruiting NCT04951583 - Fecal Microbial Transplantation Non-Small Cell Lung Cancer and Melanoma Phase 2
Recruiting NCT06112808 - A Clinical Study of the Pharmacokinetics and Safety of BCD-263 and Opdivo® as Monotherapy in Subjects With Advanced Melanoma of the Skin Phase 1
Recruiting NCT01614301 - Phase I and Consecutive Phase II, Two-arm, Randomized Multi-center Trial in Patients With Advanced Melanoma Phase 1/Phase 2
Recruiting NCT04640545 - A Study to Assess LBL-007 in Combination With Toripalimab and Axitinib Tablets Subjects With Advanced Melanoma Phase 1
Active, not recruiting NCT03086174 - Tolerability and Pharmacokinetics of Toripalimab in Combination With Axitinib in Patients With Kidney Cancer and Melanoma Phase 1